176 related articles for article (PubMed ID: 9491831)
1. Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro.
Hoggard PG; Manion V; Barry MG; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):164-7. PubMed ID: 9491831
[TBL] [Abstract][Full Text] [Related]
2. Lamivudine (3TC) phosphorylation and drug interactions in vitro.
Kewn S; Veal GJ; Hoggard PG; Barry MG; Back DJ
Biochem Pharmacol; 1997 Sep; 54(5):589-95. PubMed ID: 9337075
[TBL] [Abstract][Full Text] [Related]
3. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
4. Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro.
Hoggard PG; Sales SD; Kewn S; Sunderland D; Khoo SH; Hart CA; Back DJ
Antivir Chem Chemother; 2000 Nov; 11(6):353-8. PubMed ID: 11227992
[TBL] [Abstract][Full Text] [Related]
5. Intracellular activation of 2',3'-dideoxyinosine and drug interactions in vitro.
Kewn S; Hoggard PG; Henry-Mowatt JS; Veal GJ; Sales SD; Barry MG; Back DJ
AIDS Res Hum Retroviruses; 1999 Jun; 15(9):793-802. PubMed ID: 10381167
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
Periclou AP; Nandy P; Avramis VI
In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
[TBL] [Abstract][Full Text] [Related]
7. In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy.
Veal GJ; Barry MG; Khoo SH; Back DJ
AIDS Res Hum Retroviruses; 1997 Apr; 13(6):481-4. PubMed ID: 9100989
[TBL] [Abstract][Full Text] [Related]
8. Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro.
Hoggard PG; Kewn S; Barry MG; Khoo SH; Back DJ
Antimicrob Agents Chemother; 1997 Jun; 41(6):1231-6. PubMed ID: 9174176
[TBL] [Abstract][Full Text] [Related]
9. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.
Patick AK; Boritzki TJ; Bloom LA
Antimicrob Agents Chemother; 1997 Oct; 41(10):2159-64. PubMed ID: 9333041
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
Barry M; Mulcahy F; Merry C; Gibbons S; Back D
Clin Pharmacokinet; 1999 Apr; 36(4):289-304. PubMed ID: 10320951
[TBL] [Abstract][Full Text] [Related]
11. Lack of evidence for in vivo transformation of zidovudine triphosphate to stavudine triphosphate in human immunodeficiency virus-infected patients.
Meléndez M; Blanco R; Delgado W; García R; Santana J; García H; Rosario O; Rodríguez JF
Antimicrob Agents Chemother; 2006 Mar; 50(3):835-40. PubMed ID: 16495240
[TBL] [Abstract][Full Text] [Related]
12. Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy.
Sommadossi JP
AIDS; 1998; 12 Suppl 3():S1-8. PubMed ID: 15168717
[TBL] [Abstract][Full Text] [Related]
13. Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo.
Hoggard PG; Sales SD; Phiboonbanakit D; Lloyd J; Maher BA; Khoo SH; Wilkins E; Carey P; Hart CA; Back DJ
Antimicrob Agents Chemother; 2001 Feb; 45(2):577-82. PubMed ID: 11158757
[TBL] [Abstract][Full Text] [Related]
14. New drugs for HIV infection.
Med Lett Drugs Ther; 1996 Apr; 38(972):35-7. PubMed ID: 8606677
[TBL] [Abstract][Full Text] [Related]
15. Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes.
Janneh O; Hoggard PG; Tjia JF; Jones SP; Khoo SH; Maher B; Back DJ; Pirmohamed M
Antivir Ther; 2003 Oct; 8(5):417-26. PubMed ID: 14640389
[TBL] [Abstract][Full Text] [Related]
16. Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells.
Veal GJ; Wild MJ; Barry MG; Back DJ
Br J Clin Pharmacol; 1994 Oct; 38(4):323-8. PubMed ID: 7833221
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents.
Gulick R
AIDS; 1998; 12 Suppl 3():S17-22. PubMed ID: 15168719
[TBL] [Abstract][Full Text] [Related]
18. Pyrimidine deoxynucleoside and nucleoside reverse transcriptase inhibitor metabolism in the perfused heart and isolated mitochondria.
Morris GW; Laclair DD; McKee EE
Antivir Ther; 2010; 15(4):587-97. PubMed ID: 20587852
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
[TBL] [Abstract][Full Text] [Related]
20. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
Barry M; Gibbons S; Back D; Mulcahy F
Clin Pharmacokinet; 1997 Mar; 32(3):194-209. PubMed ID: 9084959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
